NCT02698761 A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises Status TERMINATED Phase NA
NCT02697240 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome Status COMPLETED Phase PHASE1
NCT02678143 Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease Status TERMINATED Phase PHASE1
NCT02675959 Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease Status RECRUITING Phase PHASE2
NCT02675790 Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa Status COMPLETED Phase PHASE3
NCT02651272 Macitentan in Pulmonary Hypertension of Sickle Cell Disease Status TERMINATED Phase PHASE2
NCT02633397 A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Status COMPLETED Phase PHASE2
NCT02630394 A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Status WITHDRAWN Phase PHASE1
NCT02620488 A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease Status COMPLETED Phase NA
NCT02619734 Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease Status UNKNOWN Phase PHASE1
NCT02615847 Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients Status COMPLETED Phase PHASE2
NCT02608580 Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital. Status COMPLETED Phase NA
NCT02580565 Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease Status COMPLETED Phase N/A
NCT02578017 ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease Status COMPLETED Phase NA